Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy.
Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Clin Microbiol Infect. 2015 Apr;21(4):337-43. doi: 10.1016/j.cmi.2014.11.022. Epub 2014 Dec 3.
A prospective cohort study was conducted in nine hematology wards at tertiary care centres or at university hospitals located throughout Italy from January 2009 to December 2012. All of the cases of bacterial bloodstream infection (BBSI) occurring in adult patients with hematologic malignancies were included. A total of 668 bacterial isolates were recovered in 575 BBSI episodes. Overall, the susceptibility rates of Gram-negative bacteria were 59.1% to ceftazidime, 20.1% to ciprofloxacin, 79.1% to meropenem, 85.2% to amikacin, 69.2% to gentamicin and 69.8% to piperacillin/tazobactam. Resistance to third-generation cephalosporins was found in 98/265 (36.9%) of Enterobacteriaceae isolates. Among Klebsiella pneumoniae strains, 15/43 (34.9%) were resistant to carbapenems. Of 66 Pseudomonas aeruginosa isolates, 46 (69.7%) were multidrug resistant. Overall, the susceptibility rates of Gram-positive bacteria were 97.4% to vancomycin and 94.2% to teicoplanin. Among the monomicrobial cases of BBSI, the 21-day mortality rate was significantly higher for those caused by Gram-negative bacteria compared to those caused by Gram-positive bacteria (47/278, 16.9% vs. 12/212, 5.6%; p < 0.001). Among Gram-negative bacteria, the mortality rate was significantly higher for BBSI caused by K. pneumoniae, P. aeruginosa, and Acinetobacter baumannii. Our results confirm the recently reported shift of prevalence from Gram-positive to Gram-negative bacteria as causative agents of BBSIs among patients with hematologic malignancies and highlight a worrisome increasing frequency in antimicrobial resistance among Gram-negative bacteria.
一项前瞻性队列研究于 2009 年 1 月至 2012 年 12 月在意大利各地的三级护理中心或大学医院的 9 个血液科病房进行。纳入所有发生在血液恶性肿瘤成年患者中的细菌性血流感染(BBSI)病例。共从 575 例 BBSI 发作中分离出 668 株细菌。总的来说,革兰氏阴性菌对头孢他啶的敏感性为 59.1%,对环丙沙星的敏感性为 20.1%,对美罗培南的敏感性为 79.1%,对阿米卡星的敏感性为 85.2%,对庆大霉素的敏感性为 69.2%,对哌拉西林/他唑巴坦的敏感性为 69.8%。发现 265 株肠杆菌科分离株中有 98 株(36.9%)对第三代头孢菌素耐药。在肺炎克雷伯菌菌株中,15/43(34.9%)对碳青霉烯类耐药。66 株铜绿假单胞菌中有 46 株(69.7%)为多重耐药菌。总的来说,革兰氏阳性菌对万古霉素和替考拉宁的敏感性分别为 97.4%和 94.2%。在单微生物血源性感染病例中,革兰氏阴性菌引起的 21 天死亡率明显高于革兰氏阳性菌(47/278,16.9%比 12/212,5.6%;p <0.001)。在革兰氏阴性菌中,由肺炎克雷伯菌、铜绿假单胞菌和鲍曼不动杆菌引起的 BBSI 死亡率明显更高。我们的结果证实了最近报道的从革兰氏阳性菌到革兰氏阴性菌作为血液恶性肿瘤患者 BBSI 病原体的流行率变化,并强调了革兰氏阴性菌中抗菌药物耐药性令人担忧的增加频率。